Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: An international collaboration

Nandini N. Moorthy*, Elizabeth Roy, Vamsi Kurra, Margaret G.E. Peterson, Afton L. Hassett, Thomas J.A. Lehman, Christiaan Scott, Dalia El-Ghoneimy, Shereen Saad, Reem El Feky, Sulaiman Al-Mayouf, Pavla Dolezalova, Hana Malcova, Troels Herlin, Susan Nielsen, Nico Wulffraat, Annet van Royen, Stephen D. Marks, Alexandre Belot, Jurgen BrunnerChristian Huemer, Ivan Foeldvari, Gerd Horneff, Traudel Saurenman, Silke Schroeder, Polyxeni Pratsidou-Gertsi, Maria Trachana, Yosef Uziel, Amita Aggarwal, Tamas Constantin, Rolando Cimaz, Theresa Giani, Luca Cantarini, Fernanda Falcini, Magni M. Manzoni, Angelo Ravelli, Donato Rigante, Fracnceso Zulian, Takako Miyamae, Shumpei Yokota, Juliana Sato, Claudia S. Magalhaes, Claudio A. Len, Simone Appenzeller, Oliveira O. Knupp, Cristine C. Rodrigues, Flavio Sztajnbok, Gasparello G. de Almeida, Almeida A. de Jesus, Maria M. de Arruda Campos, Clovis Silva, Calin Lazar, Gordana Susic, Tadej Avcin, Ruben Cuttica, Ruben Burgos-Vargas, Enrique Faugier, Jordi Anton, Consuelo Modesto, Liza Vazquez, Lilliana Barillas, Laura Barinstein, Gary Sterba, Irama Maldonado, Seza Ozen, Ozgur Kasapcopur, Erkan Demirkaya, Susa Benseler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Rheumatic diseases in children are associated with significant morbidity and poor health-related quality of life (HRQOL). There is no health-related quality of life (HRQOL) scale available specifically for children with less common rheumatic diseases. These diseases share several features with systemic lupus erythematosus (SLE) such as their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL scale developed for pediatric SLE will likely be applicable to children with systemic inflammatory diseases. Findings: We adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY) to Simple Measure of Impact of Illness in Youngsters (SMILY-Illness) and had it reviewed by pediatric rheumatologists for its appropriateness and cultural suitability. We tested SMILY-Illness in patients with inflammatory rheumatic diseases and then translated it into 28 languages. Conclusion: SMILY-Illness is a brief, easy to administer and score HRQOL scale for children with systemic rheumatic diseases. It is suitable for use across different age groups and literacy levels. SMILY-Illness with its available translations may be used as useful adjuncts to clinical practice and research.

Original languageEnglish
Article number49
JournalPediatric Rheumatology
Issue number1
StatePublished - 25 Nov 2014
Externally publishedYes


Dive into the research topics of 'Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: An international collaboration'. Together they form a unique fingerprint.

Cite this